CN114746118A - 用于治疗血液病症的组合物和方法 - Google Patents

用于治疗血液病症的组合物和方法 Download PDF

Info

Publication number
CN114746118A
CN114746118A CN202080079840.5A CN202080079840A CN114746118A CN 114746118 A CN114746118 A CN 114746118A CN 202080079840 A CN202080079840 A CN 202080079840A CN 114746118 A CN114746118 A CN 114746118A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
reduction
thrombocytopenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080079840.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·耶德诺克
S·桑卡拉纳拉亚南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CN114746118A publication Critical patent/CN114746118A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080079840.5A 2019-10-17 2020-10-16 用于治疗血液病症的组合物和方法 Pending CN114746118A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
US62/916,492 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Publications (1)

Publication Number Publication Date
CN114746118A true CN114746118A (zh) 2022-07-12

Family

ID=75538375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079840.5A Pending CN114746118A (zh) 2019-10-17 2020-10-16 用于治疗血液病症的组合物和方法

Country Status (11)

Country Link
US (1) US20240109957A1 (https=)
EP (1) EP4045084A4 (https=)
JP (2) JP7809056B2 (https=)
KR (1) KR20220083737A (https=)
CN (1) CN114746118A (https=)
AU (1) AU2020365132A1 (https=)
BR (1) BR112022007051A2 (https=)
CA (1) CA3157873A1 (https=)
IL (1) IL292186A (https=)
MX (1) MX2022004287A (https=)
WO (1) WO2021076991A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118259018A (zh) * 2024-03-21 2024-06-28 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CA3195798A1 (en) * 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
WO2023114763A1 (en) * 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596576A (zh) * 2011-01-20 2014-02-19 阿龙·托梅 血小板分析系统
CN104717975A (zh) * 2012-06-18 2015-06-17 奥默罗斯公司 用于治疗各种疾病和病症的抑制masp-1和/或masp-2和/或masp-3的组合物和方法
US20160145336A1 (en) * 2014-11-26 2016-05-26 Adventist Health System/Sunbelt Inc. Effector-deficient anti-cd32a antibodies
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用
CN106349390A (zh) * 2008-04-02 2017-01-25 宏观基因有限公司 Bcr‑复合体‑特异性抗体和其使用方法
CN108779171A (zh) * 2015-11-24 2018-11-09 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
HUE070383T2 (hu) * 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349390A (zh) * 2008-04-02 2017-01-25 宏观基因有限公司 Bcr‑复合体‑特异性抗体和其使用方法
CN103596576A (zh) * 2011-01-20 2014-02-19 阿龙·托梅 血小板分析系统
CN104717975A (zh) * 2012-06-18 2015-06-17 奥默罗斯公司 用于治疗各种疾病和病症的抑制masp-1和/或masp-2和/或masp-3的组合物和方法
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用
US20160145336A1 (en) * 2014-11-26 2016-05-26 Adventist Health System/Sunbelt Inc. Effector-deficient anti-cd32a antibodies
CN108779171A (zh) * 2015-11-24 2018-11-09 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.M. WAT等: "Molecular actions of heparin and their implications in preventing pre‐eclampsia", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 31 August 2018 (2018-08-31), pages 1 - 12 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118259018A (zh) * 2024-03-21 2024-06-28 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用

Also Published As

Publication number Publication date
KR20220083737A (ko) 2022-06-20
US20240109957A1 (en) 2024-04-04
EP4045084A4 (en) 2023-05-31
JP2022551751A (ja) 2022-12-13
WO2021076991A1 (en) 2021-04-22
IL292186A (en) 2022-06-01
MX2022004287A (es) 2022-07-19
JP2026028257A (ja) 2026-02-19
JP7809056B2 (ja) 2026-01-30
CA3157873A1 (en) 2021-04-22
BR112022007051A2 (pt) 2022-07-05
AU2020365132A1 (en) 2022-04-28
EP4045084A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
JP7809056B2 (ja) 血液障害を処置するための組成物及び方法
KR102626877B1 (ko) 인간화 항-보체 인자 c1q 항체 및 이의 용도
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
NZ757986A (en) Methods for treating conditions associated with masp-2 dependent complement activation
TW201842931A (zh) 用於治療補體介導之疾病及病症之方法
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
WO2018017711A1 (en) Compositions and methods for treating frontotemporal dementia
US20240141067A1 (en) Administration of Anti-HPA-1a Antibodies
JP2024503724A (ja) 免疫調節抗体およびその使用
US20230391858A1 (en) Compositions and methods for treating blood disorders
JP2021502958A (ja) 方法
HK40077291A (en) Compositions and methods for treating blood disorders
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания
CN117062835A (zh) 免疫调节性抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077291

Country of ref document: HK